Exo Therapeutics is a small-molecule drug discovery and development company leveraging its proprietary ExoSight platform to discover compounds that bind exosites—distal, unique binding pockets that can reprogram enzyme activity. The company is building a deep pipeline of drug candidates intended to provide greater selectivity, improved therapeutic windows, and fewer side effects compared with active-site or allosteric modulators. Initial programs focus on oncology and inflammation, with four initial programs referenced by the company. Exo plans to advance those therapeutic candidates toward proof-of-concept and into the clinic. Proceeds from the recent financing will also be used to expand the company’s pursuit of new targets using the ExoSight platform. Exo cites foundational work by professors David Liu and Alan Saghatelian and former student Juan Pablo Maianti as underpinning its approach and is strengthening its governance with new board additions. Exo Therapeutics develops small-molecule drugs that bind exosites — distal, unique pockets that can reprogram enzyme activity — using its proprietary ExoSight platform. ExoSight combines structural and computational biology, protein engineering, and DNA-encoded libraries to discover and optimize exosite-targeting compounds. Focusing on exosites aims to avoid competitive binding and off-target activity associated with active-site and allosteric modulators, potentially improving therapeutic windows, selectivity, and side-effect profiles. The company is advancing an initial pipeline of programs focused on oncology and inflammation and expects to discover exosites across many disease-causing pathways. Exo closed a $25 million Series A and will use proceeds to advance therapeutic candidates toward proof-of-concept and into the clinic. The company is based in Cambridge, Mass., and has assembled a scientific advisory board and leadership drawing on foundational research from Professors David Liu and Alan Saghatelian.

Total raised

$103M

Funding rounds

2

Latest round

Series B

Latest activity

Oct 2021